Vilar Jose M, Batista Miguel, Morales Manuel, Santana Angelo, Cuervo Belén, Rubio Mónica, Cugat Ramón, Sopena Joaquín, Carrillo Jose M
Department of Animal Pathology, Faculty of Veterinary Medicine, Universidad de Las Palmas de Gran Canaria, Trasmontaña S/N, Arucas, 35413 Las Palmas, Spain.
BMC Vet Res. 2014 Jul 1;10:143. doi: 10.1186/1746-6148-10-143.
Regenerative medicine using Mesenchymal Stem Cells (MSC) alone or combined with Plasma Rich in Growth Factors (PRGF) is a rapidly growing area of clinical research and is currently also being used to treat osteoarthritis (OA). Force platform analysis has been consistently used to verify and quantify the efficacy of different therapeutic strategies for the treatment of OA in dogs including MSC associated to PRGF, but never with AD-MSC alone. The aim of this study was to use a force platform to measure the efficacy of intraarticular ADMSC administration for limb function improvement in dogs with severe OA.
Ten lame dogs with severe hip OA and a control group of 5 sound dogs were used for this study. Results were statistically analyzed to detect a significant increase in peak vertical force (PVF) and vertical impulse (VI) in treated dogs. Mean values of PVF and VI were significantly improved within the first three months post-treatment in the OA group, increasing 9% and 2.5% body weight, respectively, at day 30. After this, the effect seems to decrease reaching initial values.
Intraarticular ADMSC therapy objectively improved limb function in dogs with hip OA. The duration of maximal effect was less than 3 months.
单独使用间充质干细胞(MSC)或与富含生长因子的血浆(PRGF)联合使用的再生医学是临床研究中一个快速发展的领域,目前也被用于治疗骨关节炎(OA)。力平台分析一直被用于验证和量化包括与PRGF联合使用的MSC在内的不同治疗策略对犬OA治疗的疗效,但从未单独用于脂肪来源间充质干细胞(AD-MSC)。本研究的目的是使用力平台测量关节内注射ADMSC对重度OA犬肢体功能改善的疗效。
本研究使用了10只患有严重髋部OA的跛行犬和5只健康犬作为对照组。对结果进行统计学分析,以检测治疗犬的垂直峰值力(PVF)和垂直冲量(VI)有显著增加。OA组在治疗后的前三个月内,PVF和VI的平均值显著改善,在第30天时分别增加了9%和2.5%体重。在此之后,效果似乎下降至初始值。
关节内注射ADMSC疗法客观上改善了髋部OA犬的肢体功能。最大效果的持续时间小于3个月。